Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA: Parenteral source of calories and fluid in patients requiring IV hydration; treatment of hypovolemia; prevention or correction of dehydration and electrolyte imbalances.,Off-label: Adjunctive therapy in the management of hyperkalemia (with insulin); treatment of hypoglycemia.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Glucose: ~1.5–2 hours for metabolic clearance in euglycemic individuals; prolonged in renal impairment (adds renal excretion of glucose if threshold exceeded). Dextrose solution constituents (water, sodium, chloride) have no true half-life; water turnover half-life ~3–4 hours in adults.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the citric acid cycle in all tissues; insulin-dependent cellular uptake occurs in most cells. Sodium chloride is not metabolized but is excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal elimination of free water and electrolytes. Glucose is metabolized to CO2 and water; excess glucose not metabolized is excreted renally as glucose (glucosuria) when renal threshold exceeded. Sodium and chloride are excreted renally, with >90% of filtered sodium reabsorbed; chloride follows sodium. No biliary or fecal elimination of intact drug.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Glucose: negligible binding (<1%). Sodium and chloride: not protein bound.
Low protein binding; 0–11% bound, primarily to albumin.
Glucose: Vd ~0.15–0.25 L/kg (total body water). Sodium: Vd ~0.25 L/kg (extracellular fluid). Chloride: Vd ~0.25–0.35 L/kg. Water distributes throughout total body water (~0.6 L/kg).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% bioavailable. Not applicable to oral or other routes.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
In acute kidney injury or chronic kidney disease, use with caution; monitor for volume overload and hypernatremia. GFR < 30 m L/min: restrict volume to 500-1000 m L/day with careful sodium assessment. GFR 30-50 m L/min: use standard dosing with monitoring. GFR > 50 m L/min: no adjustment required.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based dose adjustments; monitor for fluid retention and electrolyte disturbances in decompensated cirrhosis (Child-Pugh B or C). Use with caution in ascites.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based infusion: neonates 0-28 days: 5-10 m L/hour; infants 1-12 months: 10-20 m L/hour; children 1-12 years: 20-50 m L/hour; adolescents 13-17 years: 50-100 m L/hour. Adjust based on glucose and electrolyte monitoring.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients: start at lower infusion rates (50-100 m L/hour) and titrate; monitor for fluid overload, hyperglycemia, and hypernatremia due to reduced renal function and comorbid conditions. Adjust based on cardiac status and renal function.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of fluid overload in patients with congestive heart failure, renal insufficiency, or hepatic cirrhosis.,Monitor serum glucose, electrolytes, and fluid balance; dextrose can cause hyperglycemia, especially in diabetic patients.,Do not administer simultaneously with blood through same tubing due to risk of RBC aggregation/hemolysis.,Intraosseous administration may cause compartment syndrome.,Use with caution in patients with preexisting electrolyte abnormalities or those receiving corticosteroids.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia with marked glycosuria or hyperosmolar coma.,Hypersensitivity to corn or corn products.,Severe electrolyte imbalances (e.g., hypernatremia) unless corrected.,Patients with anuria not related to hypovolemia.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid high-sodium foods as this solution already contains sodium chloride. Diabetic patients should monitor carbohydrate intake, as dextrose provides 5 g/100 m L. No direct food interactions, but overall sodium and glucose intake should be considered.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for fluid and electrolyte replacement. Maternal hyperglycemia or electrolyte disturbances may indirectly affect the fetus if improperly administered, but the solution itself is not teratogenic.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Both dextrose and sodium chloride are normal constituents of breast milk. Administration of this solution does not pose a risk to the nursing infant. The M/P ratio is not applicable as these substances are endogenous and not actively concentrated in milk.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy-related plasma volume expansion and increased glomerular filtration rate may require adjustments in infusion rate to avoid fluid overload or electrolyte imbalance. Dose should be individualized based on maternal fluid status, electrolyte levels, and renal function. No standard dose adjustment is necessary but careful titration is recommended.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Contains 5 g dextrose and 0.9 g sodium chloride per 100 m L; provides 170 kcal/L and 154 m Eq/L each of Na+ and Cl-. Monitor serum glucose in diabetic patients; avoid in hyperglycemia. Use with caution in heart failure, renal impairment, and hypertension due to sodium load. Incompatible with certain drugs (e.g., amphotericin B, erythromycin).
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution provides sugar and salt to replace fluids and energy.,Tell your doctor if you have diabetes, high blood pressure, or heart or kidney problems.,You may experience swelling due to the salt content; report shortness of breath or leg swelling.,Do not consume additional salty foods unless advised by your doctor.,Your blood sugar and electrolytes will be monitored during treatment.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for flu. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.